The Association Between HLA-A*03:01 and HLA-B*07:02 Alleles and Oxcarbazepine-induced Maculopapular Eruption in the Uighur Chinese Population.

PURPOSE: To determine genetic associations between oxcarbazepine (OXC)-induced maculopapular eruption (MPE) and human leukocyte antigen (HLA) variants in the Uighur Chinese population. METHODS: A total of 208 patients were enrolled in this study, including 20 subjects with OXC-induced MPE (case group) and 188 OXC-tolerant patients (control group). We detected the whole sequence of the HLA alleles in the 208 Uighur patients using next-generation sequencing (NGS). RESULTS: The carried rate of HLA-A*03:01 was significantly different between the OXC-induced MPE group and the tolerant group (7/20, 35% versus 4/188, 2.13%; P = 0.000, odds ratio [OR] = 24.77, 95% confidence interval [CI] = 6.41-95.65). Additionally, the carried rate of HLA-B*07:02 was significantly different between the OXC-induced MPE group and the tolerant group (3/20, 15% versus 2/188, 0.011%; P = 0.000, odds ratio [OR] = 16.41, 95% confidence interval (CI) = 2.56-105.09). CONCLUSIONS: HLA-A*03:01 and HLA-B*07:02 may be the risk alleles for MPE in the Uighur Chinese population.

Association between HLA genotype and antiseizure medications (ASMs)-induced maculopapular eruption among epilepsy patients in Xinjiang, China.

PURPOSE: To determine genetic associations between antiseizure medications (ASMs)-induced maculopapular eruption (MPE) and human leukocyte antigen (HLA) variants in Xinjiang, China. METHODS: A total of 409 patients were enrolled in this study, including 36 subjects with ASMs-induced MPE (case group) and 373 ASMs-tolerant patients (control group). We detected the whole sequence of the HLA alleles in the 409 Uighur patients using next-generation sequencing (NGS). The carried rate of HLA alleles were compared between the case group, the control group, and the general Chinese population. RESULTS: The carried rate of HLA-A*03:01, HLA-B*07:02, HLA-C*01:02, and HLA-DRB1 *06:09 allele was significantly higher in the ASMs-MPE group when compared with both the ASMs-tolerant group (p = 0.000, odds ratio (OR) = 23.92, 95 % confidence interval (CI) = 3.96-74.84; p = 0.000, OR = 21.40, 95 % CI = 3.55-67.52; p = 0.030, OR = 4.69, 95 % CI = 0.90-61.73 and p = 0.000, OR = 18.94, 95 % CI = 3.15-60.58; respectively), and the general Chinese population (p = 0.000, OR = 21.34, 95 % CI = 3.31-38.98; p = 0.000, OR = 23.92, 95 % CI = 3.96-74.84; p = 0.019, OR = 5.53, 95 % CI = 0.14-19.86 and p = 0.000, OR = 21.67, 95 % CI = 3.68-11.73; respectively). Moreover, the carried rate of the HLA-B*4001 allele was significantly higher in the ASMs-tolerant group when compared with the ASMs-MPE group (p = 0.024, OR = 5.13, 95 % CI = 1.01-9.99). CONCLUSIONS: In this study, we identified for the first time that the carried rate of HLA-A*03:01, HLA-B*07:02, HLA-C*01:02, and HLA-DRB1 *06:09 allele was significantly higher in the ASMs-MPE group when compared with the ASMs-tolerant group.